CD8A and cancer: In both preclinical mouse models and in in vitro experiments with primary human cells from healthy people and advanced cancer patients, ALKS 4230 induced greater expansion and activation of NK cells and memory-phenotype CD8+T cells and decreased levels of Treg cells and proinflammatory cytokines, such as IL-6 and tumor necrosis factor (TNF).